Guidance for use of seasonal vaccines in immunocompromised patients
For immunocompromised patients, the Infectious Diseases Society of America (IDSA) maintains guidance for how to consider vaccinations for the respiratory season. This year, Force of Infection (FOI) has interpreted those recommendations and created a pictorial guide as well as “Bottom Line” recommendations for RSV, influenza and COVID-19 vaccinations. While the guidance matches that from IDSA, some may appreciate the more conversational approach in the FOI blog post.
Clinical influenza resources
Immunize.org has a treasure trove of influenza resources. A common question asked during influenza season is, “Which influenza vaccines are available, and what are key differences?” For this information, check out their helpful resource, “Influenza Vaccine Products for the 2026-2027 Influenza Season.”
Additional resources include:
- Standing orders
- Guidance for communicating about influenza vaccination
- Illustrated handouts for patients
- Ask-the-Experts questions related to influenza vaccine
- And so much more
Peruse this site to see what can be useful in your clinical practice.
Pediatric RSV recommendations
The American Academy of Pediatrics (AAP) published recommendations for the 2026-2027 RSV season in the form of a policy statement accompanied by a technical report. Most critically, clinicians should note the updated language in the policy statement related to the expanded group of children 8 to 19 months of age who are entering their second RSV season and now considered to be at high risk for severe RSV disease. The technical report details the data related to these changes.
The expanded groups include children:
- Born preterm at less than 32 weeks, 0 days’ gestation, regardless of whether they require medication or other support
- With hemodynamically significant congenital heart disease
- With anatomic pulmonary abnormalities or neuromuscular disorders that increase their risk for severe RSV disease
- With Down syndrome or other chromosomal differences that place them at higher risk
Children considered high risk in prior seasons should also continue to receive the second-year dosing. While the expansion represents a small population of children, their hospitalizations are consequential. The AAP is communicating this update to insurance companies to promote coverage this season.
Guidance for use of seasonal vaccines in immunocompromised patients
For immunocompromised patients, the Infectious Diseases Society of America (IDSA) maintains guidance for how to consider vaccinations for the respiratory season. This year, Force of Infection (FOI) has interpreted those recommendations and created a pictorial guide as well as “Bottom Line” recommendations for RSV, influenza and COVID-19 vaccinations. While the guidance matches that from IDSA, some may appreciate the more conversational approach in the FOI blog post.
Clinical influenza resources
Immunize.org has a treasure trove of influenza resources. A common question asked during influenza season is, “Which influenza vaccines are available, and what are key differences?” For this information, check out their helpful resource, “Influenza Vaccine Products for the 2026-2027 Influenza Season.”
Additional resources include:
- Standing orders
- Guidance for communicating about influenza vaccination
- Illustrated handouts for patients
- Ask-the-Experts questions related to influenza vaccine
- And so much more
Peruse this site to see what can be useful in your clinical practice.
Pediatric RSV recommendations
The American Academy of Pediatrics (AAP) published recommendations for the 2026-2027 RSV season in the form of a policy statement accompanied by a technical report. Most critically, clinicians should note the updated language in the policy statement related to the expanded group of children 8 to 19 months of age who are entering their second RSV season and now considered to be at high risk for severe RSV disease. The technical report details the data related to these changes.
The expanded groups include children:
- Born preterm at less than 32 weeks, 0 days’ gestation, regardless of whether they require medication or other support
- With hemodynamically significant congenital heart disease
- With anatomic pulmonary abnormalities or neuromuscular disorders that increase their risk for severe RSV disease
- With Down syndrome or other chromosomal differences that place them at higher risk
Children considered high risk in prior seasons should also continue to receive the second-year dosing. While the expansion represents a small population of children, their hospitalizations are consequential. The AAP is communicating this update to insurance companies to promote coverage this season.